Tags

Type your tag names separated by a space and hit enter

Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
Headache. 2018 11; 58 Suppl 3:230-237.H

Abstract

Growth in knowledge about calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine brought CGRP antagonism to headache medicine. Failures in development of small molecule CGRP receptor antagonists and increasing knowledge and use of monoclonal antibodies (mAbs) in medicine led to the breakthrough development of large molecule anti-CGRP mAbs: eptinezumab, erenumab, fremanezumab, and galcanezumab. This specifics about CGRP immunology aims to outline: (1) knowledge needed for CGRP antagonism and (2) developmental issues of specific CGRP antagonists for provider use. This clinically oriented review documents IgG structure and function; state of the art of monoclonal IgG production and ligand-antigen-antibodies in migraine therapeutics contributing to immunogenic risks and off-target toxicities. Specifics to CGRP ligand, receptor, antagonism, and molecules, small and large, complete this review. Completion will facilitate assessment of the similarities, differences, and application of the forthcoming anti-CGRP receptor and ligand antagonists for patients.

Authors+Show Affiliations

Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30187471

Citation

Taylor, Frederick R.. "Antigens and Antibodies in Disease With Specifics About CGRP Immunology." Headache, vol. 58 Suppl 3, 2018, pp. 230-237.
Taylor FR. Antigens and Antibodies in Disease With Specifics About CGRP Immunology. Headache. 2018;58 Suppl 3:230-237.
Taylor, F. R. (2018). Antigens and Antibodies in Disease With Specifics About CGRP Immunology. Headache, 58 Suppl 3, 230-237. https://doi.org/10.1111/head.13409
Taylor FR. Antigens and Antibodies in Disease With Specifics About CGRP Immunology. Headache. 2018;58 Suppl 3:230-237. PubMed PMID: 30187471.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antigens and Antibodies in Disease With Specifics About CGRP Immunology. A1 - Taylor,Frederick R, Y1 - 2018/09/05/ PY - 2018/06/04/accepted PY - 2018/9/7/pubmed PY - 2019/11/9/medline PY - 2018/9/7/entrez KW - CGRP antagonism KW - anti-CGRP monoclonal antibodies KW - cell surface G protein receptors KW - hybridoma KW - immunoglobulin gamma SP - 230 EP - 237 JF - Headache JO - Headache VL - 58 Suppl 3 N2 - Growth in knowledge about calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine brought CGRP antagonism to headache medicine. Failures in development of small molecule CGRP receptor antagonists and increasing knowledge and use of monoclonal antibodies (mAbs) in medicine led to the breakthrough development of large molecule anti-CGRP mAbs: eptinezumab, erenumab, fremanezumab, and galcanezumab. This specifics about CGRP immunology aims to outline: (1) knowledge needed for CGRP antagonism and (2) developmental issues of specific CGRP antagonists for provider use. This clinically oriented review documents IgG structure and function; state of the art of monoclonal IgG production and ligand-antigen-antibodies in migraine therapeutics contributing to immunogenic risks and off-target toxicities. Specifics to CGRP ligand, receptor, antagonism, and molecules, small and large, complete this review. Completion will facilitate assessment of the similarities, differences, and application of the forthcoming anti-CGRP receptor and ligand antagonists for patients. SN - 1526-4610 UR - https://www.unboundmedicine.com/medline/citation/30187471/Antigens_and_Antibodies_in_Disease_With_Specifics_About_CGRP_Immunology_ L2 - https://doi.org/10.1111/head.13409 DB - PRIME DP - Unbound Medicine ER -